Information de reference pour ce titreAccession Number: | 01451459-200105010-00005.
|
Author: | Belshe, Robert B. 1; Stevens, Cladd 2; Gorse, Geoffrey J. 1; Buchbinder, Susan 5; Weinhold, Kent 15; Sheppard, Haynes 6; Stablein, Donald 12; Self, Steve 8; McNamara, James 11; Frey, Sharon 1; Flores, Jorge 11; Excler, Jean Louis 14; Klein, Michel 14; El Habib, Raphaelle 14; Duliege, Anne-Marie 7; Harro, Clayton 13; Corey, Lawrence 9; Keefer, Michael 4; Mulligan, Mark 16; Wright, Peter 17; Celum, Connie 10; Judson, Frank 18; Mayer, Kenneth 19,20; McKirnan, David 21; Marmor, Michael 3; Woody, George 22; National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group and HIV Network for Prevention Trials (HIVNET)
|
Institution: | (1)Department of Internal Medicine, Saint Louis University School of Medicine and St. Louis Veterans Affairs Medical Center, St. Louis, Missouri (2)Laboratory of Epidemiology, New York Blood Center, New York (3)Department of Environmental Medicine, New York University School of Medicine, New York (4)Department of Medicine, University of Rochester Medical Center, Rochester, New York (5)San Francisco AIDS Office, Department of Public Health, San Francisco (6)VRDL, California Department of Health, Berkeley (7)Chiron Corporation, Emeryville (8)Fred Hutchinson Cancer Research Center-HIVNET Statistical Center, University of Washington, Seattle (9)Fred Hutchinson Cancer Research Center, University of Washington, Seattle (10)Department of Medicine, University of Washington, Seattle (11)Division of AIDS, National Institutes of Health, Bethesda (12)The EMMES Corporation, Potomac, Maryland (13)Center for Immunization Research, Johns Hopkins University, Baltimore, Maryland (14)Aventis-Pasteur, Marcy l'Etoile, France (15)Central Immunology Laboratory, Duke University Medical Center, Durham, North Carolina (16)Department of Medicine, University of Alabama at Birmingham (17)Department of Medicine, Vanderbilt University, Nashville, Tennessee (18)Department of Public Health, Denver, Colorado (19)Fenway Community Health, Boston, Massachusetts (20)Miriam Hospital, Providence, and Memorial Hospital, Pawtucket, Rhode Island (21)Howard Brown Health Center, Chicago, Illinois (22)University of Pennsylvania/VA Medical Center, Philadelphia
|
Title: | |
Source: | Journal of Infectious Diseases. 183(9):1343-1352, May 1, 2001.
|
Abstract: | : Live attenuated viral vectors that express human immunodeficiency virus (HIV) antigens are being developed as potential vaccines to prevent HIV infection. The first phase 2 trial with a canarypox vector (vCP205, which expresses gp120, p55, and protease) was conducted in 435 volunteers with and without gp120 boosting, to expand the safety database and to compare the immunogenicity of the vector in volunteers who were at higher risk with that in volunteers at lower risk for HIV infection. Neutralizing antibodies to the MN strain were stimulated in 94% of volunteers given vCP205 plus gp120 and in 56% of volunteers given vCP205 alone. CD8+ cytotoxic T lymphocyte cells developed at some time point in 33% of volunteers given vCP205, with or without gp120. Phase 3 field trials with these or similar vaccines are needed, to determine whether efficacy in preventing HIV infection or in slowing disease progression among vaccinees who become infected is associated with the level and types of immune responses that were induced by the vaccines in this study
(C) Copyright Oxford University Press 2001.
|
References: | 1. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative pox virus vector system. Vaccine 1996; 14:428-34.
2. Taylor J, Weinberg R, Tartaglia J, et al. Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology 1992; 187:321-8.
3. Taylor J, Meignier B, Tartaglia J, et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65), in non-avian species. Vaccine 1995; 13:539-49.
4. Musey L, Hughes J, Schacker T, Shea T, Corey L. Cytotoxic T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997; 337:1267-74.
5. Graham BS, Belshe RB, Clements ML, et al. Vaccination of vaccinia-naive adults with human immunodeficiency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. J Infect Dis 1992; 166:244-52.
6. Corey L, McElrath MJ, Weinhold K, et al. Cytotoxic T cell and neutralizing antibody responses to HIV-1 envelope with a combination vaccine regimen. J Infect Dis 1997; 176:924-32.
7. Clements-Mann ML, Weinhold K, Matthews TJ, et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp 120, HIV-1SF-2 recombinant gp120, or both vaccines in seronegative adults. J Infect Dis 1998; 177:1230-66.
8. Cooney EL, McElrath MJ, Corey L, et al. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc Natl Acad Sci USA 1993; 90:1882-6.
9. Graham BS, Matthews TJ, Belshe RB, et al. Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. J Infect Dis 1993; 167:533-7.
10. Graham BS, Gorse GJ, Schwartz DH, et al. Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. J Infect Dis 1994; 170:782-6.
11. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 1997; 11(A)S127-37.
12. Fleury B, Janvier G, Pialoux G, et al. Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp160 or HIV-1 and boosted with a recombinant gp160. J Infect Dis 1996; 174:734-8.
13. Pialoux G, Excler JL, Riviere Y, et al. The AGIS Group and IAgence Nationale de Recherche sur le SIDA: a prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). AIDS Res Hum Retroviruses 1995; 11:373-81.
14. Cadoz M, Strady A, Meignier B, et al. Immunization with canarypox virus expressing rabies glycoprotein. Lancet 1992; 339:1429-32.
15. Kahn JO, Sinangil F, Baenziger J, et al. Clinical and immunological responses to human immunodeficiency virus (HIV) type 1 SF2 gp120 subunit vaccine combined with MF59 adjuvant with or without muramyl tripeptide dipalmitoyl phosphatidylethanolamine in non-HIV-infected human volunteers. J Infect Dis 1994; 170:1288-91.
16. Koblin BA, Heagerty P, Sheon A, et al. Readiness of high-risk populations in the HIV Network for Prevention Trials to participate in HIV vaccine efficacy trials in the United States. AIDS 1998; 12:785-93.
17. Graham BS, Keefer MC, McElrath MJ, et al. and the NIAID AIDS Vaccine Evaluation Group. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adult volunteers: recombinant envelope glycoprotein gp120. Ann Intern Med 1996; 125:270-9.
18. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term non-progressors. J Infect Dis 1996; 173:60-7.
19. Pilgrim AK, Pantaleo G, Cohen OJ, et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997; 176:924-32.
20. Belshe RB, Gorse GJ, Mulligan MJ, et al. for the NIAID AIDS Vaccine Evaluation Group. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. AIDS 1998; 12:2407-15.
21. Gorse GJ, Belshe RB, Newman FK, Frey SE. and the NIAID AIDS Vaccine Clinical Trials Network. Lymphocyte proliferative responses following immunization with human immunodeficiency virus recombinant gp160. Vaccine 1992; 10:383-8.
22. Gorse GJ, Corey L, Patel GB, et al. for the NIAID AIDS Vaccine Evaluation Group. HIV-1MN recombinant glycoprotein 160 vaccine-induced cellular and humoral immunity boosted by HIV-1MN recombinant glycoprotein 120 vaccine. AIDS Res Hum Retroviruses 1999; 15:115-32.
23. Belshe RB, Clements ML, Dolin R, et al. and the NIAID AIDS Vaccine Evaluation Group Network. Safety and immunogenicity of a fully glycosylated recombinant gp160 human immunodeficiency virus type-1 vaccine in subjects at low risk of infection. J Infect Dis 1993; 168:1387-95.
24. Corey L, Weinhold K, Montefiori D, et al. Combination candidate HIV vaccines using a canarypox vector (vCP205) followed by boosting with gp120 SF-2 [abstract LB18]. Proceedings and abstracts of the 4th Conference on Retroviruses and Opportunistic Infection, Washington, DC, 1997 1997. Washington, DC: American Society for Microbiology.
25. The AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 env, gag, and pro in combination with rgp120. J Infect Dis 2001; 183:563-70.
|
Language: | English.
|
Document Type: | Major Articles.
|
ISSN: | 0022-1899
|
DOI Number: | https://dx.doi.org/10.1086/31986...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|